Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

MIRA Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ADVANCING TOWARD PHASE 2A CLINICAL EVALUATION IN CHEMOTHERAPY-RELATED PAIN, A CONDITION WITH NO APPROVED TREATMENTS AND POTENTIAL FOR FDA FAST TRACK CONSIDERATION MIAMI, FLORIDA / ACCESS NEWSWIRE / OCTOBER 24, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED THE INITIATION OF THE MULTIPLE ASCENDING DOSE (MAD) PORTION OF ITS ONGOING PHASE 1 CLINICAL TRIAL EVALUATING ITS LEAD ORAL CANDIDATE, KETAMIR-2, IN HEALTHY VOLUNTEERS. THE COMPANY ALSO ANNOUNCED THAT IT HAS SELECTED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) - A COMMON AND DEBILITATING SIDE EFFECT OF CANCER TREATMENT - AS THE LEAD INDICATION FOR ITS PLANNED PHASE 2A CLINICAL EVALUATION.

MIRA PHARMACEUTICALS INITIATES MULTIPLE ASCENDING DOSE (MAD) PHASE 1 STUDY OF ORAL KETAMIR-2 AND SELECTS CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN AS LEAD PHASE 2A INDICATION

FINDINGS SHOW ORAL MIRA-55 FULLY NORMALIZED PAIN AND SIGNIFICANTLY REDUCED INFLAMMATION, SUPPORTING IND PLANS AND REINFORCING MIRA'S POSITION IN A $70 BILLION NON-OPIOID PAIN MARKET. MIAMI, FLORIDA / ACCESS NEWSWIRE / OCTOBER 16, 2025 / MIRA PHARMACEUTICALS, INC.

MIRA PHARMACEUTICALS ANNOUNCES ORAL MIRA-55 OUTPERFORMED INJECTED MORPHINE IN NORMALIZING PAIN AND REDUCING INFLAMMATION, SUPPORTING ITS PLANNED IND FOR CHRONIC INFLAMMATORY PAIN

CLOSING ADDS $5 MILLION IN MARKETABLE SECURITIES, STRENGTHENS FINANCIAL POSITION, AND COMPLEMENTS MIRA'S ADVANCING PROGRAMS INCLUDING KETAMIR-2 AND MIRA-55 MIAMI, FLORIDA / ACCESS NEWSWIRE / SEPTEMBER 30, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED THAT IT HAS COMPLETED ITS ACQUISITION OF SKNY PHARMACEUTICALS, INC. ("SKNY"). AS PART OF THE TRANSACTION, SKNY FULFILLED ALL CLOSING OBLIGATIONS, CONTRIBUTING $5 MILLION IN MARKETABLE SECURITIES TO MIRA, FURTHER STRENGTHENING THE COMPANY'S BALANCE SHEET.

MIRA PHARMACEUTICALS CLOSES ACQUISITION OF SKNY PHARMACEUTICALS, EXPANDS PIPELINE WITH SKNY-1 FOR OBESITY AND NICOTINE ADDICTION

STUDY DEMONSTRATED KETAMIR-2 WAS SAFE AND WELL TOLERATED AT ALL DOSE LEVELS, WITH A FAVORABLE SAFETY AND TOLERABILITY PROFILE, WITH NO SEVERE OR CLINICALLY SIGNIFICANT ADVERSE EFFECTS OBSERVED. THE DRUG SHOWED RAPID AND PREDICTABLE ABSORPTION, A FAVORABLE DURATION OF ACTION SUPPORTING ONCE-DAILY DOSING, AND NO CNS SIDE EFFECTS TYPICALLY SEEN WITH KETAMINE.

MIRA PHARMACEUTICALS ANNOUNCES FAVORABLE TOPLINE RESULTS FROM PHASE 1 SAD STUDY OF ORAL KETAMIR-2, A NEXT-GENERATION NON-SCHEDULED KETAMINE ANALOG

MIRA ADVANCES KETAMIR-2 IN THE CLINIC FOR NEUROPATHIC PAIN WHILE BROADENING DEVELOPMENT INTO NEUROPSYCHIATRIC DISORDERS SUCH AS PTSD MIAMI, FLORIDA / ACCESS NEWSWIRE / SEPTEMBER 16, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED POSITIVE RESULTS DEMONSTRATING THAT ITS ORAL DRUG CANDIDATE KETAMIR-2 RESTORED NORMALIZED BEHAVIOR IN STRESSED ANIMALS WITHIN A VALIDATED MODEL OF POST-TRAUMATIC STRESS DISORDER (PTSD). KETAMIR-2 IS CURRENTLY BEING EVALUATED IN AN ONGOING PHASE 1 CLINICAL TRIAL FOR NEUROPATHIC PAIN, WHERE IT HAS SHOWN A FAVORABLE SAFETY PROFILE TO DATE.

MIRA PHARMACEUTICALS REPORTS POSITIVE PTSD DATA DEMONSTRATING KETAMIR-2 RESTORES NORMALIZED BEHAVIOR IN STRESSED ANIMALS

SKNY TRANSACTION STRENGTHENS MIRA PIPELINE WITH SKNY-1, A DIFFERENTIATED ORAL CANDIDATE THAT HAS DEMONSTRATED UP TO 30% WEIGHT LOSS AND NICOTINE CRAVING REVERSAL IN PRECLINICAL STUDIES. MIAMI, FL / ACCESS NEWSWIRE / SEPTEMBER 12, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED THAT ITS STOCKHOLDERS HAVE APPROVED THE ACQUISITION OF SKNY PHARMACEUTICALS, INC. ("SKNY") AT THE COMPANY'S 2025 ANNUAL MEETING OF STOCKHOLDERS.

MIRA PHARMACEUTICALS SHAREHOLDERS APPROVE ACQUISITION OF SKNY PHARMACEUTICALS, ADVANCING NEXT-GENERATION ORAL THERAPEUTIC FOR OBESITY AND SMOKING CESSATION

FOLLOWING FDA IND CLEARANCE FOR NEUROPATHIC PAIN, THE COMPANY IS PREPARING TO INITIATE ITS U.S. PHASE 2A TRIAL IN Q4 2025 MIAMI, FL / ACCESS NEWSWIRE / AUGUST 19, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF THE SINGLE ASCENDING DOSE (SAD) PORTION OF ITS ONGOING PHASE 1 CLINICAL TRIAL EVALUATING ORAL KETAMIR-2. THE STUDY, CONDUCTED AT THE HADASSAH CLINICAL RESEARCH CENTER IN ISRAEL UNDER THE DIRECTION OF PRINCIPAL INVESTIGATOR PROF.

MIRA PHARMACEUTICALS ANNOUNCES COMPLETION OF PHASE 1 SINGLE ASCENDING DOSE FOR ORAL KETAMIR-2 WITH NO SAFETY CONCERNS, ADVANCES TO MULTIPLE ASCENDING DOSE STAGE

MANUSCRIPT ACCEPTED FOR PUBLICATION IN FRONTIERS IN PHARMACOLOGY, "ORAL ADMINISTRATION OF KETAMIR-2, A NOVEL KETAMINE ANALOG, ATTENUATES NEUROPATHIC PAIN IN RODENT MODELS VIA SELECTIVE NMDA ANTAGONISM" DETAILS KETAMIR-2'S SUPERIOR PERFORMANCE IN TWO VALIDATED NEUROPATHIC PAIN MODELS AND SUPPORTS ADVANCEMENT TO PHASE 2A CLINICAL TRIALS BY YEAR-END 2025. MIAMI, FL / ACCESS NEWSWIRE / AUGUST 12, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE OF A SECOND PEER-REVIEWED MANUSCRIPT DESCRIBING ITS LEAD ORAL DRUG CANDIDATE, KETAMIR-2, IN FRONTIERS IN PHARMACOLOGY.

MIRA PHARMACEUTICALS' SECOND KETAMIR-2 MANUSCRIPT ACCEPTED FOR PEER-REVIEWED PUBLICATION DEMONSTRATING SUPERIOR EFFICACY IN PRECLINICAL NEUROPATHIC PAIN MODELS VERSUS KETAMINE, GABAPENTIN, OR PREGABALIN

TOPICAL KETAMIR-2 SIGNIFICANTLY REDUCED BOTH ACUTE AND INFLAMMATORY PAIN BEHAVIORS IN ANIMALS, DEMONSTRATING RAPID ONSET, DURABLE EFFECT, AND COMPARABLE EFFICACY TO INJECTED MORPHINE ACROSS BOTH PAIN PHASES MIAMI, FLORIDA / ACCESS NEWSWIRE / JULY 30, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED NEW PRECLINICAL DATA SHOWING THAT ITS TOPICAL KETAMIR-2 CREAM DELIVERED SIMILAR AND CONSISTENT PAIN RELIEF COMPARED WITH INJECTED MORPHINE IN A VALIDATED ANIMAL MODEL OF ACUTE AND INFLAMMATORY PAIN. IN THE STUDY, KETAMIR-2 CREAM WAS APPLIED TOPICALLY TO THE AFFECTED AREA 30 MINUTES BEFORE PAIN WAS INDUCED USING THE FORMALIN MODEL, A WIDELY ACCEPTED PRECLINICAL METHOD FOR EVALUATING BOTH ACUTE AND INFLAMMATORY PAIN.

MIRA Pharmaceuticals, Inc.

MIRA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MIRA Pharmaceuticals, Inc.

MIRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MIRA